Buscar
21/12/2024
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
Río, P, Zubicaray, J, Navarro, S, Gálvez, E, Sánchez-Domínguez, R, Nicoletti, E, Sebastian, E, Rothe, M, Pujol, R, Bogliolo, M, John-Neek, P, Bastone, AL, Schambach, A, Wang, W, Schmidt, M, Larcher, L, Segovia, JC, Yáñez, RM, Alberquilla, O, Diez, B, Fernández-García, M, García-García, L, Ramírez, M, Galy, A, Lefrere, F, Cavazzana, M, Leblanc, T, de Andoin, NG, López-Almaraz, R, Catala, A, Barquinero, J, Rodríguez-Perales, S, Rao, G, Surrallés, J, Soulier, J, Díaz-de-Heredia, C, Schwartz, JD, Sevilla, J, Bueren, JA. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. LANCET. 2024; 404(10471)DOI:10.1016/S0140-6736(24)01880-4. PMID:39642902. IF:88.500(Q1/1D).
20/07/2023
A self-repair history: compensatory effect of a de novo variant on the FANCA c.2778+83C & gt;G splicing mutation
Persico I., Fontana G., Faleschini M., Zanchetta M.E., Ammeti D., Cappelli E., Corsolini F., Mosa C., Guarina A., Bogliolo M., Surrallés J., Dufour C., Farruggia P., Savoia A., Bottega R.. A self-repair history: compensatory effect of a de novo variant on the FANCA c.2778+83C & gt;G splicing mutation. Frontiers in Genetics. 2023; 14DOI:10.3389/fgene.2023.1209138. PMID:37547463. IF:2.800(Q2/5D).
21/06/2023
Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders
Lee, EM, Verma, M, Palaniappan, N, Pope, EM, Lee, S, Blacher, L, Neerumalla, P, An, W, Campbell, T, Brown, C, Hurst, S, Marshall, B, Hershey, T, Nunes, V, de Heredia, ML, Urano, F. Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders. Frontiers in Genetics. 2023; 14DOI:10.3389/fgene.2023.1198171. PMID:37415600. IF:2.800(Q2/5D).
01/04/2023
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry
Dobarro, D, Donoso-Trenado, V, Sole-Gonzalez, E, Moliner-Abos, C, Garcia-Pinilla, JM, Lopez-Fernandez, S, Ruiz-Bustillo, S, Diez-Lopez, C, Castrodeza, J, Mendez-Fernandez, AB, Vaqueriza-Cubillo, D, Cobo-Marcos, M, Tobar, J, Sagasti-Aboitiz, I, Rodriguez, M, Escolar, V, Abecia, A, Codina, P, Gomez-Otero, I, Pastor, F, Marzoa-Rivas, R, Gonzalez-Babarro, E, de Juan-Baguda, J, Melendo-Viu, M, de Frutos, F, Gonzalez-Costello, J. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Failure. 2023; 10(2)DOI:10.1002/ehf2.14278. PMID:36655614. IF:3.200(Q2/3D).